ClinicalTrials.gg

Program

adrixetinib

Also written as “Q702” and “Adrixetinib”.

Its studies are mostly in Esophageal Neoplasms · Neoplasm Metastasis · Bronchiolitis Obliterans Syndrome, led by Qurient.

Furthest: phase 2, since May 20, 20223 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qurient32 open or runningphase 2since May 20, 2022Nov 19, 2020Dec 30, 2027phase 2 · NCT05438420

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2020First study: phase 1 study in Neoplasm MetastasisFirst studyNCT04648254 · 51 enrolled · United States
  2. May 20, 2022Phase 2 study in Esophageal NeoplasmsNCT05438420 · 120 enrolled · United States, South Korea
  3. Aug 11, 2025Phase 1 study in Bronchiolitis Obliterans SyndromeNCT07138196 · 18 planned · Spain

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Esophageal NeoplasmsNCT05438420
  2. Oct 23, 2029Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeNCT07138196

TargetBeta

AXL →CSF1R →read by rule
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO), Mer, and colony stimulating factor-1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07138196Bronchiolitis Obliterans Syndrome · Spain1RecruitingOct 23, 202918
NCT05438420Esophageal Neoplasms · United States, South Korea2Active, not recruitingDec 30, 2027120
NCT04648254Neoplasm Metastasis · United States1CompletedDec 23, 202551

How it is read

Names in the registry

  • “Q702”, 2 entries
  • “Adrixetinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.